Putnam Investments LLC Prothena Corp Public LTD CO Transaction History

Putnam Investments LLC

$73 Billion
Q4 2023

A detailed history of Putnam Investments LLC transactions in Prothena Corp Public LTD CO stock. As of the latest transaction made, Putnam Investments LLC holds 66,516 shares of PRTA stock, worth $1.15 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

66,516

Previous 56,613 17.49%

Holding current value

$1.15 Million

Previous $2.73 Million 11.5%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$32.31 - $52.32 $319,965 - $518,124	9,903 Added 17.49%	66,516 $2.42 Million
Q3 2023 Nov 14, 2023	BUY	$47.3 - $70.6 $183,760 - $274,281	3,885 Added 7.37%	56,613 $2.73 Million
Q2 2023 Aug 14, 2023	BUY	$48.26 - $78.59 $87,977 - $143,269	1,823 Added 3.58%	52,728 $3.6 Million
Q1 2023 May 22, 2023	SELL	$46.97 - $58.27 $680,548 - $844,274	-14,489 Reduced 22.16%	50,905 $2.47 Million
Q4 2022 Feb 14, 2023	BUY	$52.05 - $65.0 $2.64 Million - $3.29 Million	50,638 Added 343.17%	65,394 $3.94 Million
Q3 2022 Nov 14, 2022	BUY	$25.16 - $60.63 $32,003 - $77,121	1,272 Added 9.43%	14,756 $894,000
Q2 2022 Aug 15, 2022	BUY	$22.73 - $39.98 $30,390 - $53,453	1,337 Added 11.01%	13,484 $366,000
Q1 2022 May 16, 2022	BUY	$30.27 - $49.22 $18,706 - $30,417	618 Added 5.36%	12,147 $444,000
Q4 2021 Feb 14, 2022	BUY	$42.11 - $73.26 $485,486 - $844,614	11,529 New	11,529 $570,000
Q4 2017 Feb 14, 2018	SELL	$35.44 - $63.76 $9.19 Million - $16.5 Million	-259,387 Closed	0 $0
Q3 2017 Nov 14, 2017	BUY	$53.83 - $67.75 $14 Million - $17.6 Million	259,387	259,387 $16.8 Million

Others Institutions Holding PRTA

# of Institutions

180

Shares Held

42.6M

Call Options Held

77.7K

Put Options Held

92.7K

View Full List

About PROTHENA CORP PUBLIC LTD CO

Ticker PRTA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,922,800
Market Cap $815M
Description
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a human...

More about PRTA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Putnam Investments LLC, based on Form 13F filings with the SEC.

News

Stay updated on Putnam Investments LLC with notifications on news.

Account

Putnam Investments LLC Prothena Corp Public LTD CO Transaction History